COLESTID TABLETS Rx
Generic Name and Formulations:
Colestipol HCl (micronized) 1g.
Indications for COLESTID TABLETS:
Adjunct to diet to lower elevated serum total-C and LDL-C in primary hypercholesterolemia.
Do not crush, chew, or cut. Take with adequate fluids. Initially 2g once or twice daily, then increase by 2g once or twice daily at 1–2 month intervals. Usual maintenance: 2–16g/day in 1 or more divided doses.
Obtain baseline serum cholesterol, LDL-C, and triglycerides, and monitor during therapy. Consider reducing dose, discontinuing, or alternative therapy if significant increase in triglycerides occur. May need Vit. A, D and K supplementation with long-term therapy. Exclude secondary causes of hypercholesterolemia (eg, hypothyroidism, diabetes, nephrotic syndrome, dysproteinemias, obstructive liver disease, alcoholism). Constipation; increase fluid/fiber intake or add a stool softener. Hemorrhoids. Phenylketonurics (flavored Colestid). Monitor thyroid function. Pregnancy. Nursing mothers.
Bile acid sequestrant.
Reduces absorption of folic acid, fat soluble vitamins, thiazides, furosemide, tetracycline, penicillin G, gemfibrozil, mycophenolic acid, others; monitor digitalis, propranolol; give other drugs at least 1hr before or 4hrs after. May affect absorption of oral phosphate supplements, hydrocortisone.
Constipation, fecal impaction, aggravated hemorrhoids, abdominal pain/cramp, gas, indigestion, heartburn, diarrhea, nausea, vomiting, Vit. A, D, K deficiencies or hyperchloremic acidosis with prolonged use.
Unflavored 5g pkt—30, 90; Bulk—300g, 500g (w. scoop); Flavored 7.5g pkt—60; Bulk—450g (w. scoop); Tabs—120
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds